1. Biologic response-modifying agents: What is an appropriate phase I–II strategy?

   • S. K. Carter

   Editorial Pages: 207 - 210

2. Embryonic antigens and tumor cell cytolysis

   • P. C. Jones
   • N. Sidell
   • R. F. Irie

   Guest Editorials Pages: 211 - 214

3. Histocompatibility antigens and tumour antigens

   • G. Parmiani

   Guest Editorials Pages: 215 - 217

4. Variable expression of histocompatibility antigens on tumor cells

   • W. J. Martin
   • M. Imamura

   Review Pages: 219 - 223

5. A unique antigen (sigma) on sézary cells

   • Amanullah Khan
   • Sandra L. F. Burt
   • J. M. Hill

   Original Articles Pages: 225 - 230

6. Influence of T-lymphocyte deprivation on the antileukemic effect of bacillus calmette-guérin in vivo

   • L. Olsson
   • P. Ebbesen
   • J. Hesse

   Original Articles Pages: 231 - 240

7. Disseminated intravascular coagulation following intravenous Corynebacterium parvum injection in the rat

   • P. W. Johnston
   • A. W. Thomson
   • J. G. Simpson

   Original Articles Pages: 241 - 247

8. Immunogenicity alterations induced in isolated Meth A sarcoma surface membranes

   • D. L. McCollester

   Original Articles Pages: 249 - 256

9. Systemic administration of Corynebacterium parvum during sensitization to tumor alloantigen-modified response to rechallenge

   • R. I. Murahata
   • J. Zighelboim

   Original Articles Pages: 257 - 261

10. A phase I study of intrapleural Corynebacterium parvum after complete resection of bronchogenic carcinoma

    • A. J. Solan
    • S. E. Vogl
    • C. Salazar

    Original Articles Pages: 263 - 264

11. Analysis of the effect of periodate oxidation and phenol extraction on the antitumour properties of C. parvum

    • Valentina RIveros-Moreno
    • Anne Niblock

    Original Articles Pages: 265 - 272

12. Conversion of skin tests in cancer patients after a short course of treatment with a new immunostimulating compound

    • Jean-Marie Lang
    • Cathy Giron
    • René Zalisz

    Letter To The Editors Pages: 273 - 274